| First Author | Fuchs C | Year | 2015 |
| Journal | Neurobiol Dis | Volume | 82 |
| Pages | 298-310 | PubMed ID | 26143616 |
| Mgi Jnum | J:227428 | Mgi Id | MGI:5700456 |
| Doi | 10.1016/j.nbd.2015.06.018 | Citation | Fuchs C, et al. (2015) Inhibition of GSK3beta rescues hippocampal development and learning in a mouse model of CDKL5 disorder. Neurobiol Dis 82:298-310 |
| abstractText | Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in a rare neurodevelopmental disorder characterized by early-onset seizures, severe developmental delay, intellectual disability and Rett syndrome-like features. CDKL5 is highly expressed in the brain during early postnatal stages, suggesting its importance for brain maturation. Using a newly-generated Cdkl5 knockout (Cdkl5 -/Y) mouse, we recently found that loss of Cdkl5 impairs postnatal hippocampal development with a reduction in neuronal precursor survival and maturation. These defects were accompanied by increased activity of the glycogen synthase kinase 3beta (GSK3beta) a crucial inhibitory regulator of many neurodevelopmental processes. The goal of the current study was to establish whether inhibition of GSK3beta corrects hippocampal developmental defects due to Cdkl5 loss. We found that treatment with the GSK3beta inhibitor SB216763 restored neuronal precursor survival, dendritic maturation, connectivity and hippocampus-dependent learning and memory in the Cdkl5 -/Y mouse. Importantly, these effects were retained one month after treatment cessation. At present, there are no therapeutic strategies to improve the neurological defects of subjects with CDKL5 disorder. Current results point at GSK3beta inhibitors as potential therapeutic tools for the improvement of abnormal brain development in CDKL5 disorder. |
